2 3 4-TRI-O-BENZYL-1-S-ETHYL-β-L-THI& - CAS 116391-11-8

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
Main Product
Product Name
2 3 4-TRI-O-BENZYL-1-S-ETHYL-β-L-THI&
Catalog Number
116391-11-8
Synonyms
2 3 4-TRI-O-BENZYL-1-S-ETHYL-BETA-L-THI&; 2,3,4-TRI-O-BENZYL-1-S-ETHYL-BETA-L-THIO; 2,3,4-tri-o-benzyl-1-s-ethyl-β-l-thiofucopyranoside
CAS Number
116391-11-8
Molecular Weight
478.65
Molecular Formula
C29H34O4S
Quantity
Data not available, please inquire.
COA
Inquire
MSDS
Inquire
Canonical SMILES
CCSC1C(C(C(C(O1)C)OCC2=CC=CC=C2)OCC3=CC=CC=C3)OCC4=CC=CC=C4
InChI
InChI=1S/C29H34O4S/c1-3-34-29-28(32-21-25-17-11-6-12-18-25)27(31-20-24-15-9-5-10-16-24)26(22(2)33-29)30-19-23-13-7-4-8-14-23/h4-18,22,26-29H,3,19-21H2,1-2H3/t22-,26+,27+,28-,29?/m0/s1
InChIKey
RZVKVTBAQRMTEH-JAGXECETSA-N
Structure
CAS 116391-11-8 2 3 4-TRI-O-BENZYL-1-S-ETHYL-β-L-THI&
Specification
Purity
95%
Boiling Point
592.1ºC at 760 mmHg
Melting Point
52-54ºC(lit.)
Density
1.16g/cm3
Reference Reading
1.Two small yellowish papules in a 1 year-old boy: cutaneous leishmaniasis.
Noguera-Morel L1, Azorin D, Xirotagaros G. Dermatol Online J. 2016 Mar 16;22(3). pii: 13030/qt6357d3zm.
Cutaneous leishma iasis (CL) is zoonosis with a spectrum of cutaneous manifestations caused by protozoan parasites of thegenus Leishmania.Manifestation varies according to the parasite virulence and the host immune response. Pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been used as a first-line therapy for the last 70 years around the world.We report a case of a 1-year-old boy with two small yellowish papules mimicking juvenile xantogranuloma diagnosed with cutaneous leishmaniasis after a biopsy. Patient underwent treatment with 2 sessions of intralesional (IL) meglumine antimoniate (Glucantime®) with complete clearance of both lesions.
2.Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
Scheinfeld N1, Sundaram M, Teixeira H, Gu Y, Okun M. Dermatol Online J. 2016 Mar 16;22(3). pii: 13030/qt38x5922j.
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease with frequent comorbidities of painand depression. Adalimumab treatment for 16 weeks improved HS lesions significantly versus placebo (NCT00918255).OBJECTIVE: The relationship between pain and depressive symptoms and the effects of adalimumab on each was examined in this post hoc analysis.
2005 - BOC Sciences | All rights reserved
DOWNLOAD